The authors reply

We thank Rico-Fontalvo et  al. for their interest in our study.1 The goal of our study was to assess the effect of newer nephroprotective agents on endpoints defined by different estimated glomerular filtration rate (eGFR) decline thresholds (40%, 50%, and 57% eGFR decline) to inform the design of future trials of chronic k idney disease (CKD) progression. We therefore pooled data from 4 trials that recruited patients with CKD who were at high risk of progression, and we demonstrated that the relative effects of newer nephroprotective therapies appear to be generally similar across different eGFR decline thresholds.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research